Previous close | 0.0100 |
Open | 0.0100 |
Bid | 0.0000 |
Ask | 0.1600 |
Strike | 23.50 |
Expiry date | 2024-06-28 |
Day's range | 0.0100 - 0.0200 |
Contract range | N/A |
Volume | |
Open interest | 52 |
Following the label expansion, Sarepta's (SRPT) Elevidys is approved to treat all DMD patients aged four years and older, regardless of ambulation status.
The biopharmaceutical company says the drug was approved for ambulatory and non-ambulatory people, who are at least 4 years old, and with a confirmed mutation in the DMD gene.
Sarepta stock rocketed Friday after hitting a "grand slam" approval that expands the market for its Duchenne muscular dystrophy gene therapy more than tenfold, according to one estimate.